These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

173 related items for PubMed ID: 20845519

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Nodular lymphocyte-predominant Hodgkin lymphoma.
    Savage KJ, Mottok A, Fanale M.
    Semin Hematol; 2016 Jul; 53(3):190-202. PubMed ID: 27496311
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Does functional imaging distinguish nodular lymphocyte-predominant hodgkin lymphoma from T-cell/histiocyte-rich large B-cell lymphoma?
    Barber NA, Loberiza FR, Perry AM, Bast M, Holdeman KP, Esfahane AB, Weisenburger DD, Vose J, Bierman P, Armitage JO, Bociek RG.
    Clin Lymphoma Myeloma Leuk; 2013 Aug; 13(4):392-7. PubMed ID: 23773450
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Nodular lymphocyte predominant Hodgkin lymphoma: pathology, clinical course and relation to T-cell/histiocyte rich large B-cell lymphoma.
    Hartmann S, Eichenauer DA.
    Pathology; 2020 Jan; 52(1):142-153. PubMed ID: 31785822
    [Abstract] [Full Text] [Related]

  • 11. Unfavorable presentation but comparable outcome: Presentation and outcome of children with nodular lymphocyte predominant Hodgkin lymphoma from India.
    Prasad M, Narula G, Chinnaswamy G, Arora B, Shet T, Panjwani P, Sengar M, Laskar S, Khanna N, Banavali S.
    Pediatr Blood Cancer; 2018 Oct; 65(10):e27288. PubMed ID: 29893471
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Long-term follow-up of 2 patients treated with 90 Y-rituximab radioimmunotherapy for relapse of nodular lymphocyte-predominant Hodgkin lymphoma.
    Golstein SC, Muylle K, Vercruyssen M, Spilleboudt C, de Wind A, Bron D.
    Eur J Haematol; 2018 Sep; 101(3):415-417. PubMed ID: 29719928
    [Abstract] [Full Text] [Related]

  • 15. Epidemiology of classic and nodular lymphocyte predominant hodgkin lymphoma in Finland in 1996-2015.
    Juntikka T, Malila N, Ylöstalo T, Merikivi M, Jyrkkiö S.
    Acta Oncol; 2020 May; 59(5):574-581. PubMed ID: 31910680
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Modern principles in the management of nodular lymphocyte-predominant Hodgkin lymphoma.
    Spinner MA, Varma G, Advani RH.
    Br J Haematol; 2019 Jan; 184(1):17-29. PubMed ID: 30485408
    [Abstract] [Full Text] [Related]

  • 18. Immunoarchitectural patterns in nodular lymphocyte predominant Hodgkin lymphoma: pathologic and clinical implications.
    Gloghini A, Bosco A, Ponzoni M, Spina M, Carbone A.
    Expert Rev Hematol; 2015 Apr; 8(2):217-23. PubMed ID: 25487651
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. [Nodular lymphocyte-predominant Hodgkin's lymphoma: Principles of diagnosis and treatment].
    Moiseeva TN, Al-Radi LS, Kovrigina AM, Goryacheva SR, Julakyan UL, Margolin OV, Skidan NI, Tseytlina MA, Kravchenko SK.
    Ter Arkh; 2015 Apr; 87(11):78-83. PubMed ID: 26821421
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.